- Home
- HYMC vs KROS Comparison
HYMC vs KROS Comparison
Compare HYMC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYMC
- KROS
- Stock Information
- Founded
- HYMC N/A
- KROS 2015
- Country
- HYMC United States
- KROS United States
- Employees
- HYMC N/A
- KROS N/A
- Industry
- HYMC Precious Metals
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- HYMC Basic Materials
- KROS Health Care
- Exchange
- HYMC Nasdaq
- KROS Nasdaq
- Market Cap
- HYMC 648.5M
- KROS 565.0M
- IPO Year
- HYMC N/A
- KROS 2020
- Fundamental
- Price
- HYMC $7.62
- KROS $15.55
- Analyst Decision
- HYMC
- KROS Buy
- Analyst Count
- HYMC 0
- KROS 14
- Target Price
- HYMC N/A
- KROS $20.56
- AVG Volume (30 Days)
- HYMC 2.0M
- KROS 1.2M
- Earning Date
- HYMC 10-28-2025
- KROS 11-06-2025
- Dividend Yield
- HYMC N/A
- KROS N/A
- EPS Growth
- HYMC N/A
- KROS N/A
- EPS
- HYMC N/A
- KROS 0.47
- Revenue
- HYMC N/A
- KROS $232,844,000.00
- Revenue This Year
- HYMC N/A
- KROS $6,657.47
- Revenue Next Year
- HYMC N/A
- KROS N/A
- P/E Ratio
- HYMC N/A
- KROS $33.41
- Revenue Growth
- HYMC N/A
- KROS 85820.30
- 52 Week Low
- HYMC $1.99
- KROS $9.12
- 52 Week High
- HYMC $9.75
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- HYMC 53.27
- KROS 54.40
- Support Level
- HYMC $7.44
- KROS $14.86
- Resistance Level
- HYMC $8.18
- KROS $15.30
- Average True Range (ATR)
- HYMC 0.72
- KROS 0.62
- MACD
- HYMC -0.09
- KROS 0.05
- Stochastic Oscillator
- HYMC 35.18
- KROS 90.49
About HYMC Hycroft Mining Holding Corporation
Hycroft Mining Holding Corp is a gold and silver producer. Its operating mine, the Hycroft Mine, is an open-pit heap leach operation located approximately fifty four miles west of Winnemucca, Nevada.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.